Literature DB >> 17825550

Persistent low urinary excretion of 5-HIAA is a marker for favourable survival during follow-up in patients with disseminated midgut carcinoid tumours.

Anouk N A van der Horst-Schrivers1, Wendy J Post, Ido P Kema, Thera P Links, Pax H B Willemse, A N Machteld Wymenga, Elisabeth G E de Vries.   

Abstract

Survival of patients with disseminated midgut carcinoid tumours varies. We investigated which factors predict survival at referral and during follow-up, with emphasis on urinary 5-hydroxyindolacetic acid (5-HIAA) levels. Between 1992 and 2003, 76 patients were studied; urine was prospectively collected over a 24 h period every 3 months in order to measure 5-HIAA levels. Uni- and multivariate analyses were performed. Median follow-up was 55 months with a median survival of 54 months. Prognostic factors for poor survival were high age, high gamma-glutamyltransferase levels and greatly increased 5-HIAA levels (>20 mmol/mol creatinine) The Hazard Ratio (HR) of a greatly increased 5-HIAA level was 3.33 (95% confidence interval (CI) 1.66-6.66, p=0.001). In a multivariate survival analysis with the 5-HIAA level as time dependent covariable, the HR for the 5-HIAA level was 1.007 (95% CI 1.004-1.010, p=0.000). In conclusion, patients with persistent moderately increased urinary 5-HIAA levels (< or =20 mmol/mol creatinine) have favourable outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17825550     DOI: 10.1016/j.ejca.2007.07.025

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  Management of gastrointestinal carcinoid tumours - 10 years experience at a district general hospital.

Authors:  Shridhar S Dronamraju; Vickram B Joypaul
Journal:  J Gastrointest Oncol       Date:  2012-06

2.  Is Resection of Primary Midgut Neuroendocrine Tumors in Patients with Unresectable Metastatic Liver Disease Justified? A Systematic Review and Meta-Analysis.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Ioannis D Kostakis; Demetrios Moris; Dimitrios Schizas; Jordan M Cloyd; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2019-01-22       Impact factor: 3.452

Review 3.  The use of biomarkers in neuroendocrine tumours.

Authors:  Mohid Shakil Khan; Martyn E Caplin
Journal:  Frontline Gastroenterol       Date:  2013-03-21

4.  Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.

Authors:  Lowell B Anthony; Matthew H Kulke; Martyn E Caplin; Emily Bergsland; Kjell Öberg; Marianne Pavel; Dieter Hörsch; Richard R P Warner; Thomas M O'Dorisio; Joseph S Dillon; Pablo Lapuerta; Kenneth Kassler-Taub; Wenjun Jiang
Journal:  Oncologist       Date:  2019-01-16

5.  Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.

Authors:  Marianne E Pavel; Alexandria T Phan; Edward M Wolin; Beloo Mirakhur; Nilani Liyanage; Susan Pitman Lowenthal; George A Fisher; Aaron I Vinik
Journal:  Oncologist       Date:  2018-10-24

Review 6.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

Review 7.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

8.  Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors.

Authors:  Amit Tirosh; Naris Nilubol; Dhaval Patel; Electron Kebebew
Journal:  Endocr Pract       Date:  2018-08-07       Impact factor: 3.443

9.  Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.

Authors:  Kosmas Daskalakis; Andreas Karakatsanis; Ola Hessman; Heather C Stuart; Staffan Welin; Eva Tiensuu Janson; Kjell Öberg; Per Hellman; Olov Norlén; Peter Stålberg
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

Review 10.  The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.

Authors:  Catherine G Tran; Scott K Sherman; James R Howe
Journal:  Ann Surg Oncol       Date:  2021-01-15       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.